WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H318291
CAS#: 186826-86-8 (HCl)
Description: Moxifloxacin is a fourth-generation synthetic fluoroquinolone antibacterial agent. Its antibacterial spectrum includes enteric Gram-(−) rods (Escherichia coli, Proteus species, Klebsiella species), Haemophilus influenzae, atypical bacteria (Mycoplasma, Chlamydia, Legionella), and Streptococcus pneumoniae, and anaerobic bacteria. It differs from earlier antibacterials of the fluoroquinolone class such as levofloxacin and ciprofloxacin in having greater activity against Gram-positive bacteria and anaerobes. Because of its potent activity against the common respiratory pathogen Streptococcus pneumoniae, it is considered a "respiratory quinolone."
Hodoodo Cat#: H318291
Name: Moxifloxacin HCl
CAS#: 186826-86-8 (HCl)
Chemical Formula: C21H25ClFN3O4
Exact Mass: 0.00
Molecular Weight: 437.900
Elemental Analysis: C, 57.60; H, 5.75; Cl, 8.10; F, 4.34; N, 9.60; O, 14.61
Related CAS #: 151096-09-2 (free base) 186826-86-8 (HCl) 192927-63-2 (HCl hydrate)
Synonym: BAY12-8039; BAY 12-8039; BAY-12-8039; BAY128039; BAY-128039; BAY 128039; Moxifloxacin, Avelox, Avalox, Avelon, Vigamox, Moxeza
IUPAC/Chemical Name: 7-[(4aS,7aS)-1,2,3,4,4a,5,7,7a-octahydropyrrolo[3,4-b]pyridin-6-yl]-1-cyclopropyl-6-fluoro-8-methoxy-4-oxoquinoline-3-carboxylic acid hydrochloride
InChi Key: IDIIJJHBXUESQI-DFIJPDEKSA-N
InChi Code: InChI=1S/C21H24FN3O4.ClH/c1-29-20-17-13(19(26)14(21(27)28)9-25(17)12-4-5-12)7-15(22)18(20)24-8-11-3-2-6-23-16(11)10-24;/h7,9,11-12,16,23H,2-6,8,10H2,1H3,(H,27,28);1H/t11-,16+;/m0./s1
SMILES Code: O=C(C1=CN(C2CC2)C3=C(C=C(F)C(N(C4)C[C@]5([H])[C@@]4([H])CCCN5)=C3OC)C1=O)O.[H]Cl
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO, not in water
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
| Biological target: | Moxifloxacin Hydrochloride (BAY 12-8039) is an 8-methoxyquinolone antimicrobial for use in the treatment of acute bacterial sinusitis, acute bacterial exacerbations of chronic bronchitis, and community-acquired pneumonia. |
| In vitro activity: | The in vitro activity of the fluoroquinolone BAY 12-8039 against 66 strains of different mycoplasma species and 30 strains of Ureaplasma urealyticum was compared with those of three other antimicrobial agents. BAY 12-8039 at 0.5 μg/ml inhibited 100% of all the mycoplasmal and ureaplasmal strains tested. BAY 12-8039 was fourfold more active than clarithromycin but two- to fourfold less active than sparfloxacin. Furthermore, the activity of BAY 12-8039 was compared with that of sparfloxacin against the eight multistep fluoroquinolone-resistant mutants of the reference strain M. hominis PG21. A comparable increased resistance to both antibiotics was found (MIC of BAY 12-8039, 1 to 8 μg/ml; MIC of sparfloxacin, 0.06 to 4 μg/ml). BAY 12-8039 was very active against all the ureaplasma strains studied. Doxycycline-resistant strains were as susceptible as doxycycline-susceptible strains to BAY 12-8039. For all mycoplasma species (Table1), the MBCs of BAY 12-8039 were two- to eightfold higher than the MICs. These data suggest that BAY 12-8039 may be useful for the treatment of respiratory or genital infections in which mycoplasmas are involved. Antimicrob Agents Chemother. 1998 Mar; 42(3): 703–704. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC105523/ |
| In vivo activity: | Moxifloxacin treatment resulted in an increased clearance of P. aeruginosa and S. pneumoniae in the lungs of mice infected with viable bacteria indicating a bactericidal activity of moxifloxacin in our pneumonia model against both bacterial species. No viable bacteria were detected in BAL fluids of moxifloxacin-treated mice infected with 5 × 106 CFU of S. pneumoniae 24 hours post infection, whereas 7 × 103 (±3 × 103) CFU of viable S. pneumoniae were determined in BAL fluids of saline-treated control mice. In mice infected with 107 CFU of P. aeruginosa for 6 hours, 4 × 105 (±2 × 105) CFU were detected in BAL fluids of saline-treated control mice and 9 × 102 (±1.3 × 103) CFU in BAL fluids of moxifloxacin-treated mice. Interestingly, treatment with moxifloxacin affected the levels of total immune cells and neutrophils in the lungs of mice infected with viable and heat-inactivated bacteria. Treatment with moxifloxacin, as compared to saline, resulted in significantly reduced levels of total immune cells (Figure 1A to C) and neutrophils (Figure 2A to C) in BAL fluids of mice infected with a low dose or a high dose of heat-inactivated P. aeruginosa or with viable S. pneumoniae (Figures 1E and2E). There was no difference in the numbers of total immune cells in BAL fluids between moxifloxacin- and saline-treated mice infected with viable P. aeruginosa (Figures 1D and 2D). Levels of macrophages and lymphocytes in BAL fluids were not affected by treatment with moxifloxacin (data not shown). In conclusion, it is shown that moxifloxacin reduces the “hyper-inflammation” during murine pneumonia. Pretreatment with moxifloxacin attenuates local and systemic inflammation during bacterial pneumonia in mice. Respir Res. 2014; 15(1): 82. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4118268/ |
| Solvent | Max Conc. mg/mL | Max Conc. mM | |
|---|---|---|---|
| Solubility | |||
| Soluble in DMSO | 10.0 | 22.80 |
The following data is based on the product molecular weight 437.90 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
| Formulation protocol: | 1.Bébéar CM, Renaudin H, Boudjadja A, Bébéar C. In vitro activity of BAY 12-8039, a new fluoroquinolone against mycoplasmas. Antimicrob Agents Chemother. 1998 Mar;42(3):703-4. doi: 10.1128/AAC.42.3.703. PMID: 9517957; PMCID: PMC105523. 2. Fass RJ. In vitro activity of Bay 12-8039, a new 8-methoxyquinolone. Antimicrob Agents Chemother. 1997 Aug;41(8):1818-24. doi: 10.1128/AAC.41.8.1818. PMID: 9257770; PMCID: PMC164014. |
| In vitro protocol: | 1.Bébéar CM, Renaudin H, Boudjadja A, Bébéar C. In vitro activity of BAY 12-8039, a new fluoroquinolone against mycoplasmas. Antimicrob Agents Chemother. 1998 Mar;42(3):703-4. doi: 10.1128/AAC.42.3.703. PMID: 9517957; PMCID: PMC105523. 2. Fass RJ. In vitro activity of Bay 12-8039, a new 8-methoxyquinolone. Antimicrob Agents Chemother. 1997 Aug;41(8):1818-24. doi: 10.1128/AAC.41.8.1818. PMID: 9257770; PMCID: PMC164014. 3. Ukpo GE, Ebuehi OA, Kareem AA. Evaluation of Moxifloxacin-induced Biochemical Changes in Mice. Indian J Pharm Sci. 2012 Sep;74(5):454-7. doi: 10.4103/0250-474X.108422. PMID: 23716875; PMCID: PMC3660873. 4. Beisswenger C, Honecker A, Kamyschnikow A, Bischoff M, Tschernig T, Bals R. Moxifloxacin modulates inflammation during murine pneumonia. Respir Res. 2014 Jul 17;15(1):82. doi: 10.1186/1465-9921-15-82. PMID: 25034539; PMCID: PMC4118268. |
| In vivo protocol: | 1. Ukpo GE, Ebuehi OA, Kareem AA. Evaluation of Moxifloxacin-induced Biochemical Changes in Mice. Indian J Pharm Sci. 2012 Sep;74(5):454-7. doi: 10.4103/0250-474X.108422. PMID: 23716875; PMCID: PMC3660873. 2. Beisswenger C, Honecker A, Kamyschnikow A, Bischoff M, Tschernig T, Bals R. Moxifloxacin modulates inflammation during murine pneumonia. Respir Res. 2014 Jul 17;15(1):82. doi: 10.1186/1465-9921-15-82. PMID: 25034539; PMCID: PMC4118268 |
1: Gillespie SH. The role of moxifloxacin in tuberculosis therapy. Eur Respir Rev. 2016 Mar;25(139):19-28. doi: 10.1183/16000617.0085-2015. Review. PubMed PMID: 26929417.
2: Chen Z, Liang JQ, Wang JH, Feng SS, Zhang GY. Moxifloxacin plus standard first-line therapy in the treatment of pulmonary tuberculosis: A meta-analysis. Tuberculosis (Edinb). 2015 Jul;95(4):490-6. doi: 10.1016/j.tube.2015.03.014. Epub 2015 Apr 16. Review. PubMed PMID: 25964137.
3: Ovchinnikov AY, Edzhe MA, Miroshnichenko NA, Hon EM, Korostelev SA. [15-year experience of moxifloxacin in the treatment of patients with bacterial rhinosinusitis]. Vestn Otorinolaringol. 2015;80(3):75-9. Review. Russian. PubMed PMID: 26331163.
4: Chilet-Rosell E, Ruiz-Cantero MT, Pardo MA. Gender analysis of moxifloxacin clinical trials. J Womens Health (Larchmt). 2014 Jan;23(1):77-104. doi: 10.1089/jwh.2012.4171. Epub 2013 Nov 1. Review. PubMed PMID: 24180298; PubMed Central PMCID: PMC3881443.
5: Linertová R, Abreu-González R, García-Pérez L, Alonso-Plasencia M, Cordovés-Dorta LM, Abreu-Reyes JA, Serrano-Aguilar P. Intracameral cefuroxime and moxifloxacin used as endophthalmitis prophylaxis after cataract surgery: systematic review of effectiveness and cost-effectiveness. Clin Ophthalmol. 2014 Aug 14;8:1515-22. doi: 10.2147/OPTH.S59776. eCollection 2014. Review. PubMed PMID: 25152613; PubMed Central PMCID: PMC4140229.
6: Al Omari MM, Jaafari DS, Al-Sou'od KA, Badwan AA. Moxifloxacin hydrochloride. Profiles Drug Subst Excip Relat Methodol. 2014;39:299-431. doi: 10.1016/B978-0-12-800173-8.00007-6. Review. PubMed PMID: 24794910.
7: O'Brien DP, Comte E, Ford N, Christinet V, du Cros P. Moxifloxacin for Buruli ulcer/HIV coinfected patients: kill two birds with one stone? AIDS. 2013 Sep 10;27(14):2177-9. doi: 10.1097/QAD.0b013e32836268f4. Review. PubMed PMID: 24157903.
8: Chen F, Zheng N, Wang Y, Wen JL, Tu WF, Du YQ, Lin JM. Sequential intravenous/oral moxifloxacin monotherapy for complicated skin and skin structure infections: a meta-analysis of randomised controlled trials. Int J Clin Pract. 2013 Sep;67(9):834-42. doi: 10.1111/ijcp.12174. Review. PubMed PMID: 23952463.
9: Zhang G, Zou J, Liu F, Bao Z, Dong F, Huang Y, Yin S. The efficacy of moxifloxacin-based triple therapy in treatment of Helicobacter pylori infection: a systematic review and meta-analysis of randomized clinical trials. Braz J Med Biol Res. 2013 Jul;46(7):607-13. doi: 10.1590/1414-431X20132817. Epub 2013 Jul 16. Review. PubMed PMID: 23903685; PubMed Central PMCID: PMC3859334.
10: Dawson R, Diacon A. PA-824 , moxifloxacin and pyrazinamide combination therapy for tuberculosis. Expert Opin Investig Drugs. 2013 Jul;22(7):927-32. doi: 10.1517/13543784.2013.801958. Epub 2013 May 21. Review. PubMed PMID: 23687915.
11: Wilson R, Macklin-Doherty A. The use of moxifloxacin for acute exacerbations of chronic obstructive pulmonary disease and chronic bronchitis. Expert Rev Respir Med. 2012 Nov;6(5):481-92. doi: 10.1586/ers.12.50. Epub 2012 Oct 31. Review. PubMed PMID: 23113693.
12: Mittal SO, Machado DG, Jabbari B. Orofacial dyskinesia after moxifloxacin treatment--a case with normal hepatorenal function and review of literature. Clin Neuropharmacol. 2012 Nov-Dec;35(6):292-4. doi: 10.1097/WNF.0b013e31826ba0eb. Review. PubMed PMID: 23151468.
13: Morshedi RG, Bettis DI, Moshirfar M, Vitale AT. Bilateral acute iris transillumination following systemic moxifloxacin for respiratory illness: report of two cases and review of the literature. Ocul Immunol Inflamm. 2012 Aug;20(4):266-72. doi: 10.3109/09273948.2012.670359. Epub 2012 Jun 13. Review. PubMed PMID: 22694259.
14: [Moxifloxacin (Kanavig), ophthalmic administration]. J Pharm Belg. 2012 Jun;(2):41-2. Review. French. PubMed PMID: 22978015.
15: Mu YP, Liu RL, Wang LQ, Deng X, Zhu N, Wei MD, Wang Y. Moxifloxacin monotherapy for treatment of complicated intra-abdominal infections: a meta-analysis of randomised controlled trials. Int J Clin Pract. 2012 Feb;66(2):210-7. doi: 10.1111/j.1742-1241.2011.02839.x. Review. PubMed PMID: 22257046.
16: Lau YJ, Chen YH, Huang CT, Lee WS, Liu CY, Liu JW, Liu HD, Lee YJ, Chen CW, Ko WC, Hsueh PR. Role of moxifloxacin for the treatment of community-acquired [corrected] complicated intra-abdominal infections in Taiwan. J Microbiol Immunol Infect. 2012 Feb;45(1):1-6. doi: 10.1016/j.jmii.2011.11.010. Epub 2012 Jan 12. Review. Erratum in: J Microbiol Immunol Infect. 2012 Aug;45(4):328. PubMed PMID: 22244019.
17: Fouad M, Gallagher JC. Moxifloxacin as an alternative or additive therapy for treatment of pulmonary tuberculosis. Ann Pharmacother. 2011 Nov;45(11):1439-44. doi: 10.1345/aph.1Q299. Epub 2011 Oct 11. Review. PubMed PMID: 21990937.
18: Keating GM. Moxifloxacin 0.5% ophthalmic solution: in bacterial conjunctivitis. Drugs. 2011 Jan 1;71(1):89-99. doi: 10.2165/11205840-000000000-00000. Review. PubMed PMID: 21175242.
19: Cheadle W, Lee JT, Napolitano LM, Nichols RL. Clinical update on the use of moxifloxacin in the treatment of community-acquired complicated intraabdominal infections. Surg Infect (Larchmt). 2010 Oct;11(5):487-94. doi: 10.1089/sur.2009.062. Review. PubMed PMID: 20583956.
20: Simoens S. Evidence for moxifloxacin in community-acquired pneumonia: the impact of pharmaco-economic considerations on guidelines. Curr Med Res Opin. 2009 Oct;25(10):2447-57. doi: 10.1185/03007990903223663. Review. PubMed PMID: 19678752.
